Mental Health DailyResearch. Evidence. Perspective.Published research on vyvanse.
Binge-eating disorder (BED), characterized by recurrent episodes of overeating without compensatory behaviors, is a significant global health concern. Lisdexamfetamine dimesylate (LDX), the …
Read articleVyvanse (Lisdexamfetamine) is a prodrug comprised of the amino acid L-lysine coupled with dextroamphetamine, hence its chemical name “lis-dexamfetamine.” As a prodrug, Vyvanse is inactive un…
Read articleVyvanse (Lisdexamfetamine) is a psychostimulant medication manufactured by Shire Pharmaceuticals for the treatment of ADHD (attention-deficit/hyperactivity disorder). Many consider Vyvanse t…
Read articleVyvanse (Lisdexamfetamine) is a drug developed by Shire Pharmaceuticals as a successor to Adderall. Vyvanse was first approved for the treatment of attention-deficit/hyperactivity disorder (…
Read articleMethylphenidate is considered the first medication approved for the treatment of the condition known as “hyperactivity” in the 1960s. As attention-deficit/hyperactivity disorder gained more …
Read articleWith the increasing number of ADHD diagnoses, many individuals are turning to pharmaceutical psychostimulant medications as a means to alleviate symptoms. Historically, one of the most popul…
Read articleAs of February 2015, the FDA approved the psychostimulant Vyvanse (Lisdexamfetamine) for the treatment of binge eating disorder. In recent years, the popularity of Vyvanse has skyrocketed as…
Read article